Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 2
1982 1
1984 2
1986 1
1987 1
1988 1
1992 1
1995 1
1996 1
1997 2
1999 2
2000 1
2002 1
2003 1
2006 2
2007 3
2011 2
2013 1
2014 1
2015 1
2016 2
2017 2
2018 1
2022 1
2023 1
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
[Pheochromocytoma and shock].
Quietzsch D. Quietzsch D. Z Gesamte Inn Med. 1982 Jan 1;37(1):32-4. Z Gesamte Inn Med. 1982. PMID: 6280403 German.
[Immunomodulation with apheresis technics].
Liebert A, Quietzsch D, Zimmermann S. Liebert A, et al. Among authors: quietzsch d. Allerg Immunol (Leipz). 1986;32(1):5-18. Allerg Immunol (Leipz). 1986. PMID: 2940851 Review. German.
[Neuroendocrine Neoplasia within the German NET Registry].
Im Namen aller Teilnehmer/innen am Deutschen NET-Registers; Authors; Kollaboratoren:. Im Namen aller Teilnehmer/innen am Deutschen NET-Registers, et al. Z Gastroenterol. 2018 Oct;56(10):1237-1246. doi: 10.1055/a-0661-6099. Epub 2018 Oct 10. Z Gastroenterol. 2018. PMID: 30304748 German.
Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice.
Luecke S, Fottner C, Lahner H, Jann H, Zolnowski D, Quietzsch D, Grabowski P, Cremer B, Maasberg S, Pape UF, Mueller HH, Gress TM, Rinke A, The Members Of The German Net Registry. Luecke S, et al. Among authors: quietzsch d. Cancers (Basel). 2022 May 31;14(11):2718. doi: 10.3390/cancers14112718. Cancers (Basel). 2022. PMID: 35681701 Free PMC article.
Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer.
Haas M, Ormanns S, Baechmann S, Remold A, Kruger S, Westphalen CB, Siveke JT, Wenzel P, Schlitter AM, Esposito I, Quietzsch D, Clemens MR, Kettner E, Laubender RP, Jung A, Kirchner T, Boeck S, Heinemann V. Haas M, et al. Among authors: quietzsch d. Br J Cancer. 2017 May 23;116(11):1462-1469. doi: 10.1038/bjc.2017.115. Epub 2017 Apr 27. Br J Cancer. 2017. PMID: 28449008 Free PMC article.
Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group.
Weiss L, Fischer LE, Heinemann V, Gieseler F, Hoehler T, Mayerle J, Quietzsch D, Reinacher-Schick A, Schenk M, Seipelt G, Siveke JT, Stahl M, Kaiser U, Waldschmidt DT, Dorman K, Zhang D, Westphalen CB, Boeck S, Haas M. Weiss L, et al. Among authors: quietzsch d. ESMO Open. 2024 Apr;9(4):102944. doi: 10.1016/j.esmoop.2024.102944. Epub 2024 Mar 18. ESMO Open. 2024. PMID: 38503144 Free PMC article.
Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?
Weiss L, Heinemann V, Fischer LE, Gieseler F, Hoehler T, Mayerle J, Quietzsch D, Reinacher-Schick A, Schenk M, Seipelt G, Siveke JT, Stahl M, Vehling-Kaiser U, Waldschmidt DT, Dorman K, Zhang D, Westphalen CB, von Bergwelt-Baildon M, Boeck S, Haas M. Weiss L, et al. Among authors: quietzsch d. Clin Transl Oncol. 2024 May;26(5):1268-1272. doi: 10.1007/s12094-023-03323-1. Epub 2023 Oct 4. Clin Transl Oncol. 2024. PMID: 37794220 Free PMC article.
Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.
Fischer von Weikersthal L, Schalhorn A, Stauch M, Quietzsch D, Maubach PA, Lambertz H, Oruzio D, Schlag R, Weigang-Köhler K, Vehling-Kaiser U, Schulze M, Truckenbrodt J, Goebeler M, Mittermüller J, Bosse D, Szukics B, Grundeis M, Zwingers T, Giessen C, Heinemann V. Fischer von Weikersthal L, et al. Among authors: quietzsch d. Eur J Cancer. 2011 Jan;47(2):206-14. doi: 10.1016/j.ejca.2010.09.022. Eur J Cancer. 2011. PMID: 20971632 Clinical Trial.
Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment).
Modest DP, Schulz C, von Weikersthal LF, Quietzsch D, von Einem JC, Schalhorn A, Vehling-Kaiser U, Laubender RP, Giessen C, Stintzing S, Heinemann V. Modest DP, et al. Among authors: quietzsch d. Anticancer Drugs. 2014 Feb;25(2):212-8. doi: 10.1097/CAD.0000000000000041. Anticancer Drugs. 2014. PMID: 24201305 Clinical Trial.
35 results